ESMO Asia
-
HUTCHMED to Present Clinical Data at the 2025 ESMO Asia Congress and ASH Annual Meeting
HUTCHMED will unveil new clinical data at ESMO Asia (Dec 5‑7, 2025, Singapore) and ASH (Dec 6‑9, 2025, Orlando). Highlights include first‑in‑human results for the anti‑CD47 antibody HMPL‑A83, Phase II FRUSICA‑2 readouts of fruquintinib + sintilimab in second‑line renal cell carcinoma, Phase II data on surufatinib + camrelizumab + chemotherapy for metastatic pancreatic cancer, and the final Phase III analysis of sovleplenib (ESLIM‑01) in chronic primary immune thrombocytopenia. These disclosures mark key milestones for the company’s oncology and immune‑mediated pipelines.
